Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2009

View Archived Issues

Multiple phase I studies of Exelixis oncolytic products reported

Promising phase I and II data on foretinib in solid tumor therapy

Novel ZAP-70 inhibitors in early development at Cellzone

Novel platinum compounds disclosed by sanofi-aventis for cancer therapy

Bayer Schering Pharma claims novel HIF prolyl hydroxylase inhibitors

Abbott presents GSK-3beta inhibitors for the treatment of Alzheimer's disease

Pazopanib increases visual acuity in phase II macular degeneration study

Apixaban nears regulatory submission in Europe

FDA approves new formulation of omeprazole

CPX-351 safety appears acceptable in older patients with acute myeloid leukemia

Pfizer's p38 MAPK inhibitor PHA-666859 shows potential to treat diabetic retinopathy

biOasis Technologies and Fleet Bioprocessing develop Alzheimer's disease test

Rufinamide efficacious in adults and children with epilepsy

FDA approves SonoCine automated whole-breast ultrasound method

Pharming completes pre-BLA meeting with FDA for Rhucin in hereditary angioedema

Novo Nordisk in-licenses IL-21 monoclonal antibody from ZymoGenetics

Dow Chemical forms independent company Pfenex to develop recombinant proteins

National Fragile X Foundation awards grant to UC Davis M.I.N.D. Institute

BHR Pharma files IND with FDA for progesterone in traumatic brain injury

Hemodynamic Therapeutics completes phase II trial of HTI-101 in hypertension

FDA approves Octapharma's Wilate for treatment of von Willebrand disease

FDA approves Tris Pharma's two NDAs for clonidine ER suspension and tablets

AEterna Zentaris reports results from phase III Z-036 efficacy trial of cetrorelix in BPH

EnVivo reports results from study of EVP-0962 in Alzheimer's disease

Vissane approved in Europe for endometriosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...